Talseth T, Schrumpf E, Ulrichsen H
Nephron. 1983;33(4):244-7. doi: 10.1159/000182961.
Gastric secretion (volume, pepsin and acid output) was measured in the basal state and during graded doses of intravenous pentagastrin (0.02, 0.2 and 2 micrograms/kg/h) in 5 patients with moderate to severe renal failure. On one occasion they also received intravenous cimetidine (1.5 mg/kg bolus followed by 0.5 mg/kg/h). Sustained cimetidine concentrations of approximately 2 micrograms/ml (8 nmol/ml) were associated with a 75-90% inhibition of stimulated acid output, reflecting both a reduction in volume and a lower acid concentration. Pepsin output was less depressed by cimetidine, as the pepsin concentration of the gastric juice actually increased in response to combined pentagastrin and cimetidine administration. It is concluded that renal failure, although affecting cimetidine pharmacokinetics, does not appreciably alter the response to the drug.
对5例中重度肾衰竭患者在基础状态下以及静脉注射不同剂量（0.02、0.2和2微克/千克/小时）的五肽胃泌素期间的胃分泌（分泌量、胃蛋白酶和酸分泌量）进行了测量。他们还曾接受过一次静脉注射西咪替丁（1.5毫克/千克推注，随后0.5毫克/千克/小时）。西咪替丁持续浓度约为2微克/毫升（8纳摩尔/毫升）时，刺激酸分泌量受到75 - 90%的抑制，这既反映了分泌量的减少，也反映了酸浓度的降低。胃蛋白酶分泌量受西咪替丁的抑制作用较小，因为在联合使用五肽胃泌素和西咪替丁后，胃液中的胃蛋白酶浓度实际上有所增加。得出的结论是，肾衰竭虽然会影响西咪替丁的药代动力学，但不会明显改变对该药物的反应。
